Results 71 to 80 of about 14,341,796 (262)

CD8+ T-cell responses to Theileria parva are preferentially directed to a single dominant antigen:Implications for parasite strain-specific immunity [PDF]

, 2009
Although immunodominance of CD8(+) T-cell responses is a well-recognised feature of viral infections, its role in responses to more antigenically complex pathogens is less clear.
Connelley, T., Burrells, A, W. Ivan Morrison, Declan J. McKeever, Connelley, Timothy, Taracha, Evans L., Connelly, T, McKeever, DJ, Morrison, WI, Simon P. Graham, Burrells, A., MacHugh, ND, McKeever, D J, Taracha, E.L.N., Niall D. MacHugh, Roger Pelle, Ellis, SA, McKeever, Declan J., MacHugh, N D, Connelley, T, Evans L. Taracha, Ellis, S A, Graham, SP, Pelle, Roger, Ellis, Shirley A., MacHugh, Niall D., Formisano, Principia, Formisano, P, Principia Formisano, Taracha, EL, Ellis, S.A., Shirley A. Ellis, Taracha, E L, Alison Burrells, Pelle, R, IAH, Graham, Simon P., Graham, S P, Timothy Connelley, Formisano, P., Royal (Dick) School of Veterinary Studies, ILRI, Morrison, W. Ivan, Burrells, Alison, Graham, S.P.   +44 more
core   +1 more source

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy

eLife, 2014
Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4+ autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon ...
Rhoanne C McPherson, Joanne E Konkel, Catriona T Prendergast, John P Thomson, Raffaele Ottaviano, Melanie D Leech, Oliver Kay, Stephanie E J Zandee, Claire H Sweenie, David C Wraith, Richard R Meehan, Amanda J Drake, Stephen M Anderton   +12 more
doaj   +1 more source

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

OncoImmunology, 2020
Although anti-programmed death-1 (PD-1) treatment has shown remarkable anti-tumor efficacy, immune-related adverse events (irAEs) develop with heterogeneous clinical manifestations.
Kyung Hwan Kim, Joon Young Hur, Jinhyun Cho, Bo Mi Ku, Jiae Koh, June Young Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Eui-Cheol Shin   +11 more
doaj   +1 more source

Survival After Hematopoietic Stem Cell Transplantation in Diamond–Blackfan Anemia Syndrome: The Role of Iron Overload—A Systematic Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We assessed the effect of iron overload (IO) on mortality and complications following hematopoietic stem cell transplantation (HSCT) in patients with Diamond–Blackfan anemia syndrome (DBAS) in a systematic review of individual participant data and cohort data from observational studies.
Geoffrey Z. L. Kuppens, Evangelia Kiakou, Lieke de Zwart, Maurizio Miano, Eduard J. van Beers, Marc Bierings, Marije Bartels   +6 more
wiley   +1 more source

HLA-B*35-restricted CD8(+)-T-cell epitope in Mycobacterium tuberculosis Rv2903c.

, 2002
Few human CD8(+) T-cell epitopes in mycobacterial antigens have been described to date. Here we have identified a novel HLA-B*35-restricted CD8(+) T-cell epitope in Mycobacterium tuberculosis Rv2903c based on a reverse immunogenetics approach.
Lukey, Pauline T, Abdulrahman S. Hammond, McAdam, Keith PWJ, Klein, Michèl R, Jaye, Assan, Smith, Steve M, Michèl R. Klein, Assan Jaye, Steve M. Smith, Hammond, Abdulrahman S, Pauline T. Lukey, Keith P. W. J. McAdam   +11 more
core   +1 more source

MicroRNAs affecting the susceptibility of melanoma cells to CD8+ T cell‐mediated cytolysis

Clinical and Translational Medicine, 2023
Background The regulatory functions of microRNAs (miRNAs) in anti‐tumour immunity have been mainly described in immune effector cells. Since little is known about miRNA effects on the susceptibility of target cells during T cell—target cell interaction ...
Antonino A. Pane, Theresa Kordaß, Agnes Hotz‐Wagenblatt, Elke Dickes, Annette Kopp‐Schneider, Rainer Will, Barbara Seliger, Wolfram Osen, Stefan B. Eichmüller   +8 more
doaj   +1 more source

Specific T-cell Activation in an Unspecific T-cell Repertoire [PDF]

Science Progress, 2011
T-cells are a vital type of white blood cell that circulate around our bodies, scanning for cellular abnormalities and infections. They recognise disease-associated antigens via a surface receptor called the T-cell antigen receptor (TCR). If there were a specific TCR for every single antigen, no mammal could possibly contain all the T-cells it needs ...
Berg, Hugo van den , Molina-Paris, Carmen, Sewell, Andrew K.   +2 more
openaire   +2 more sources

The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study

Blood and Lymphatic Cancer: Targets and Therapy, 2021
Qiuju Liu,1 Brittny Major,2 Jennifer Le-Rademacher,2 Aref A Al-Kali,3 Hassan Alkhateeb,3 Kebede Begna,3 Michelle A Elliott,3 Naseema Gangat,3 William J Hogan,3 C Christopher Hook,3 Scott H Kaufmann,3 Animesh Pardanani,3 Mrinal S Patnaik,3 Ayalew Tefferi ...
Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR   +16 more
doaj  

CAR-T Cell Therapy for T-Cell Malignancies.

Mediterranean journal of hematology and infectious diseases
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas,
Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone   +4 more
openaire   +3 more sources

Beyond the Document: A Single‐Center Qualitative Study of Survivorship Care Plan Barriers and Opportunities Across Pediatric Oncology Stakeholders

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survivorship care plans (SCPs) summarize cancer treatment and guide risk‐based follow‐up for cancer survivors, yet remain difficult to create, share, and use. Stakeholder perspectives are needed to inform usable approaches.
Molly S. Talman, Emma Fleisher, Megan E. Salwei, Debra Friedman, Laurie Novak   +4 more
wiley   +1 more source